Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

To join this study, you need to have been diagnosed with moderate to severe hidradenitis suppurativa (HS) for at least 6 months. Your HS must affect at least two different body areas, and at least one of these areas must be quite severe (Hurley Stage II or III). You also need to have tried and not responded well to oral antibiotics for your HS, or couldn't take them for some reason.

You might be able to join if you haven't taken 'biologic' medicines before for your HS, or if you have tried them. At the start of the study, you should have at least 5 painful lumps or inflamed nodules, and no more than 20 draining tunnels (tunnels under the skin that release pus or fluid).

However, you cannot join if you have other serious skin conditions that might make it hard to tell if the HS is improving, or if you have a history of serious infections, weakened immune system, previous organ or stem cell transplants, or certain heart problems. You also can't participate if you have a history of specific neurological conditions or certain types of cancer that haven't been fully treated.

If you decide to take part in this study, your involvement could last for just under a year, specifically up to about 60 weeks. However, if you are invited to continue into a longer-term part of the study, your initial participation might be shorter, around 52 weeks.

Throughout the study, you'll have regular visits to the clinic where you'll be given the study medicine (either brivekimig or placebo). The main treatment period, where you'll receive the study drug, will last for up to about 48 weeks. During these visits, the study team will carefully check your HS symptoms, ask about your general health, and carry out tests to make sure the medicine is safe and working as expected.